ABSTRACT
Objective This living systematic review aims to provide a timely, rigorous and continuously updated summary of the available evidence on the role of cell-based therapies in the treatment of patients with COVID-19.
Data sources We conducted searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L-OVE (Living OVerview of Evidence). L-OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L-OVE was adapted to expand the range of evidence it covers and customised to group all COVID-19 evidence in one place. All the searches covered the period until April 23, 2020 (one day before submission).
Eligibility criteria for selecting studies and methods We adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question. We searched for randomised trials evaluating the effect of cell-based therapies versus placebo or no treatment in patients with COVID-19. Anticipating the lack of randomised trials directly addressing this question, we also searched for trials evaluating other coronavirus infections, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19. Two reviewers independently screened each study for eligibility.
A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it every time the conclusions change or whenever there are substantial updates.
Results We screened 1,043 records but no study was considered eligible.
We identified 61 ongoing studies, including 39 randomised trials evaluating different types of cell-based therapies in COVID-19.
Conclusions We did not find any studies that met our inclusion criteria and hence there is no evidence to support or refute the use of cell-based therapies in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision makers in the near future.
PROSPERO Registration number CRD42020179711
Linked resources in this Living Systematic Review Common protocol
Linked resources in this Living Systematic Review Common protocol Common protocol for the systematic reviews and overviews of systematic reviews being conducted by the COVID-19 L·OVE Working Group.
Living review
Living review Web version of this systematic review, presented in a ‘living systematic review format’. This means it is continuously updated as soon as new evidence emerges.
Living OVerview of Evidence - L·OVE
Living OVerview of Evidence - L·OVE An open platform that uses artificial intelligence and a broad network of contributors to identify all of the evidence relevant to this and other healthcare questions, including those related to COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was not commissioned by any organisation and did not receive external funding. Epistemonikos Foundation is providing training, support and tools at no cost for all the members of the COVID-19 L.OVE Working Group.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
COVID-19 L·OVE Working Group
Data Availability
All data related to the project will be available. Epistemonikos Foundation will grant access to data.
